Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Int J Gynecol Cancer. 2023 Nov 6;33(11):1675-1681. doi: 10.1136/ijgc-2023-004454.
Endometrial cancer is the most common gynecologic malignancy in developed countries, with increasing incidence and mortality rates worldwide. While most cases are successfully treated with surgery, first-line treatment options for metastatic or recurrent endometrial cancer involve significant toxicities. Imprecise classification of heterogeneous subgroups further complicates treatment decisions and interpretation of clinical trial results. Recent advances in molecular classification are guiding treatment decisions for metastatic or recurrent endometrial cancers. Integrating molecular characteristics with traditional clinicopathology can both reduce overtreatment or undertreatment and help guide the appropriate choice of therapies and effective design of future studies. Here we discuss the treatment of metastatic or recurrent low-grade endometrioid adenocarcinoma of the uterine corpus, which is distinct from high-grade tumors histologically, molecularly, and in treatment response.
子宫内膜癌是发达国家最常见的妇科恶性肿瘤，其全球发病率和死亡率呈上升趋势。虽然大多数病例通过手术成功治疗，但转移性或复发性子宫内膜癌的一线治疗选择涉及重大毒性。异质亚组分类不精确进一步使治疗决策和临床试验结果的解释复杂化。分子分类的最新进展指导着转移性或复发性子宫内膜癌的治疗决策。将分子特征与传统临床病理相结合，既能减少过度治疗或治疗不足，又有助于指导治疗方法的合理选择和未来研究的有效设计。本文我们讨论了转移性或复发性低级别子宫内膜样腺癌的治疗，该肿瘤在组织学、分子水平和治疗反应上与高级别肿瘤不同。
